Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05005273




Registration number
NCT05005273
Ethics application status
Date submitted
9/08/2021
Date registered
13/08/2021
Date last updated
28/02/2024

Titles & IDs
Public title
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Scientific title
A Phase 2 Randomized Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
2021-000039-29
Secondary ID [2] 0 0
CA020-016
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Nivolumab
Treatment: Drugs - Ipilimumab
Treatment: Drugs - BMS-986207
Other interventions - Placebo

Experimental: Arm A -

Experimental: Arm B -


Treatment: Drugs: Nivolumab
Specified dose on specified days

Treatment: Drugs: Ipilimumab
Specified dose on specified days

Treatment: Drugs: BMS-986207
Specified dose on specified days

Other interventions: Placebo
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival by BICR
Timepoint [1] 0 0
From first dose to progression or death, 2.3 months
Secondary outcome [1] 0 0
Progression Free Survival by Investigator
Timepoint [1] 0 0
From first dose to progression or death, 2.3 months
Secondary outcome [2] 0 0
Overall Response Rate (ORR) by BICR
Timepoint [2] 0 0
From first dose to progression or death, 2.3 months
Secondary outcome [3] 0 0
Overall Response Rate (ORR) by Investigator
Timepoint [3] 0 0
From first dose to progression or death, 2.3 months
Secondary outcome [4] 0 0
Duration of Response (DOR) by Investigator
Timepoint [4] 0 0
From first dose to progression or death, 2.3 months
Secondary outcome [5] 0 0
Overall Survival (OS)
Timepoint [5] 0 0
From randomization to time of death, 2.3 months
Secondary outcome [6] 0 0
Number of Participants Who Had AEs, SAEs, AEs Leading to Discontinuation and Deaths.
Timepoint [6] 0 0
From first dose to progression or death, 2.3 months

Eligibility
Key inclusion criteria
- Histologically confirmed metastatic 1L Stage IV non-small cell lung cancer (NSCLC) of
squamous or nonsquamous histology

- No prior systemic anti-cancer treatment given as primary therapy for advanced or
metastatic NSCLC

- Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 20
unstained slides of tumor tissue obtained during screening or prior to enrollment

- Life expectancy of at least 3 months at the time of first dose
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase
(ALK), or c-ros oncogene 1 (ROS-1) mutations which are sensitive to available targeted
inhibitor therapy. Participants with nonsquamous histology and unknown EGFR, ALK, or
ROS-1 status are also excluded

- Participants with known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF) V600E
mutations that are sensitive to available targeted inhibitor therapy. Participants
with unknown or indeterminate BRAF mutation status are eligible.

- Untreated central nervous system metastases

- Leptomeningeal metastases (carcinomatous meningitis)

- Concurrent malignancy requiring treatment

- Active, known, or suspected autoimmune disease

- Interstitial lung disease

- Uncontrolled or significant cardiovascular disease

Other protocol-defined inclusion/exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/10/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/12/2022
Sample size
Target
Accrual to date
Final
1
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Local Institution - 0063 - Orange
Recruitment hospital [2] 0 0
Local Institution - 0056 - Wahroonga
Recruitment hospital [3] 0 0
Local Institution - 0052 - Warrnambool
Recruitment postcode(s) [1] 0 0
2800 - Orange
Recruitment postcode(s) [2] 0 0
0 - Wahroonga
Recruitment postcode(s) [3] 0 0
3280 - Warrnambool
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Idaho
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
South Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Wisconsin
Country [10] 0 0
Argentina
State/province [10] 0 0
Buenos Aires
Country [11] 0 0
Argentina
State/province [11] 0 0
Santa FE
Country [12] 0 0
Argentina
State/province [12] 0 0
San Juan
Country [13] 0 0
Belgium
State/province [13] 0 0
Antwerpen
Country [14] 0 0
Belgium
State/province [14] 0 0
Charleroi
Country [15] 0 0
Belgium
State/province [15] 0 0
Mons
Country [16] 0 0
Belgium
State/province [16] 0 0
Sint-Niklaas
Country [17] 0 0
Chile
State/province [17] 0 0
Metropolitana
Country [18] 0 0
Chile
State/province [18] 0 0
Valparaiso
Country [19] 0 0
France
State/province [19] 0 0
Limoges
Country [20] 0 0
France
State/province [20] 0 0
Nantes
Country [21] 0 0
France
State/province [21] 0 0
Pessac
Country [22] 0 0
France
State/province [22] 0 0
Rouen
Country [23] 0 0
France
State/province [23] 0 0
Saint Priest en Jarez
Country [24] 0 0
France
State/province [24] 0 0
Suresnes
Country [25] 0 0
France
State/province [25] 0 0
Toulon
Country [26] 0 0
Germany
State/province [26] 0 0
Bayern
Country [27] 0 0
Germany
State/province [27] 0 0
Hessen
Country [28] 0 0
Germany
State/province [28] 0 0
Gera
Country [29] 0 0
Germany
State/province [29] 0 0
Muenchen
Country [30] 0 0
Germany
State/province [30] 0 0
Wiesbaden
Country [31] 0 0
Israel
State/province [31] 0 0
Haifa
Country [32] 0 0
Israel
State/province [32] 0 0
Jerusalem
Country [33] 0 0
Italy
State/province [33] 0 0
MB
Country [34] 0 0
Italy
State/province [34] 0 0
MI
Country [35] 0 0
Italy
State/province [35] 0 0
Milano
Country [36] 0 0
Italy
State/province [36] 0 0
Naples
Country [37] 0 0
Italy
State/province [37] 0 0
Padova
Country [38] 0 0
Poland
State/province [38] 0 0
Bydgoszcz
Country [39] 0 0
Poland
State/province [39] 0 0
Lodz
Country [40] 0 0
Poland
State/province [40] 0 0
Otwock
Country [41] 0 0
Poland
State/province [41] 0 0
Szczecin
Country [42] 0 0
Spain
State/province [42] 0 0
Madrid
Country [43] 0 0
Spain
State/province [43] 0 0
Alicante
Country [44] 0 0
Spain
State/province [44] 0 0
Barcelona
Country [45] 0 0
Spain
State/province [45] 0 0
Jaen
Country [46] 0 0
Turkey
State/province [46] 0 0
Istanbul
Country [47] 0 0
Turkey
State/province [47] 0 0
Izmir
Country [48] 0 0
Turkey
State/province [48] 0 0
Samsun
Country [49] 0 0
Turkey
State/province [49] 0 0
Yuregir

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the safety and efficacy of BMS-986207 in
combination with nivolumab and ipilimumab as first-line treatment for participants with stage
IV non-small cell lung cancer (NSCLC).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05005273
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries